Anti-SARS-CoV-2 spike protein monoclonal antibody

(Xevudy/ Sotrovimab)

Anti-SARS-CoV-2 spike protein monoclonal antibody

Drug updated on 10/23/2023

Dosage FormInjection (intravenous: 500 mg/8 mL (62.5 mg/mL))
Drug ClassMonoclonal antibodies
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

Product Monograph / Prescribing Information

Document TitleYearSource
Sotrovimab (anti-SARS-CoV-2 spike protein monoclonal antibody) Prescribing Information.2023GlaxoSmithKline Inc., Mississauga, Ontario

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
A living WHO guideline on drugs for COVID-19.2020WHO